Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by Righttothetopon Dec 17, 2020 7:14am
101 Views
Post# 32126164

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TGA approves CBD down scheduling.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TGA approves CBD down scheduling.LABS cannot be punished any further than it has given what the financials are.  They can't ship Stada goods without EUGMP, which is wholly contingent on whether the German regulator comes across to validate....which, given the COVID circumstances, seems like a stretch and is completely outside the control of the business.  Had COVID not happened, EUGMP would have been achieved months ago and we would be talking a different tune, but it didn't happen and likely won't happen until COVID simmers down.

The clock is indeed ticking, but there is more time left than that, and I would hope our BoD have a few timeouts to yet call.

Fladdi may have a point that a merger may be floated about, it was always likely going to happen regardless, but it was always eat or be eaten.....which will LABS be?  It needs to recover a fair bit before anything M&A related makes any sense.  Hopefully our Board agrees.

Lemoyne wrote: No doubt time is running out, but not merger wise, more like if they don't manage to make significant intl sales increase in Q1, they will be seriously punished.

Especially if they do not ship stada material in Q1.


<< Previous
Bullboard Posts
Next >>